MT-2 (Melanotan II)
All information below is drawn from preclinical research literature and is provided for educational and informational purposes only. It does not constitute medical advice, imply therapeutic outcomes, or endorse any specific application.
Chemical Identification
Property
Value
Overview
General Research Context
MT-2 (Melanotan II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). In laboratory research, it has been studied for its interactions with melanocortin receptor subtypes (MC1R through MC5R) in preclinical binding assays and receptor selectivity studies.
The compound features a macrocyclic lactam bridge structure and is examined in receptor pharmacology studies as a non-selective melanocortin receptor ligand.
Areas of Investigation
Observed Interactions and Background
In receptor binding assays, MT-2 has been characterized as a non-selective agonist at multiple melanocortin receptor subtypes. Published literature has examined its binding affinities across MC1R, MC3R, MC4R, and MC5R in isolated receptor preparations.
The cyclic structure of MT-2, formed by a lactam bridge between Asp and Lys residues, restricts the conformational flexibility of the peptide. Researchers have studied this structural feature in the context of beta-turn geometry and its relationship to melanocortin receptor docking models. These observations are derived from preclinical receptor pharmacology studies.
Laboratory Notes
Synthesis and Stability Notes
The synthesis of MT-2 requires highly advanced macrocyclization techniques. Following the linear assembly of the peptide on the solid resin support, a highly specific lactam bridge must be chemically formed between the side chains of the aspartic acid (Asp) and lysine (Lys) residues prior to final cleavage. This critical macrocyclization dramatically restricts the conformational flexibility of the peptide, rigidly enforcing the exact, highly-active beta-turn geometry required for the molecule to perfectly dock into the target melanocortin receptors.
Disclaimer: All information provided herein is strictly for educational and laboratory research reference purposes only. Saga does not endorse, interpret, or evaluate these preclinical studies for any specific in vivo application or human therapeutic outcome.